Table 2. Estimated cost and disease impact of pneumococcal vaccination with PCV10 and PCV13 in Kenyan infants born in 2010.
Without PCV10 | PCV10 Introduction | PCV13 Introduction | |
Pneumococcal disease episodes * | |||
Meningitis | 3,180 | 1,659 | 1,308 |
Sepsis | 3,449 | 1,626 | 1,229 |
Bacteraemic pneumonia | 6,221 | 3,602 | 3,027 |
Non-bacteraemic pneumonia | 83,537 | 48,310 | 40,497 |
Total disease episodes | 96,387 | 55,197 | 46,061 |
Total reduction in disease episodes | – | 41,190 | 50,326 |
Pneumococcal deaths * | |||
Meningitis | 2,275 | 1,186 | 934 |
Sepsis | 1,448 | 684 | 576 |
Bacteraemic pneumonia | 2,612 | 1,513 | 1,270 |
Non-bacteraemic pneumonia | 8,077 | 4,671 | 3,916 |
Total pneumococcal deaths | 14,412 | 8,054 | 6,636 |
Total reduction in pneumococcal deaths | – | 6,358 | 7,776 |
Pneumococcal vaccination costs (2010 US$) | |||
Pneumococcal vaccine procurement cost | – | $13,662,205 | $13,662,205 |
Injection equipment cost (syringes, safety boxes) | – | $360,306 | $360,306 |
Annualized cold chain expansion costs | – | $14,758 | $70,714 |
Total costs of vaccination | – | $14,037,268 | $14,093,224 |
The number of pneumococcal deaths and episodes are non-discounted.